BiotechTube

VIVITROL (Naltrexone extended-release injectable suspension) + Placebo

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Cocaine Dependence

Conditions

Cocaine Dependence, Alcohol Dependence

Trial Timeline

Jul 1, 2009 → Sep 1, 2013

NCT ID
NCT00777062

About VIVITROL (Naltrexone extended-release injectable suspension) + Placebo

VIVITROL (Naltrexone extended-release injectable suspension) + Placebo is a phase 2 stage product being developed by Alkermes for Cocaine Dependence. The current trial status is completed. This product is registered under clinical trial identifier NCT00777062. Target conditions include Cocaine Dependence, Alcohol Dependence.

What happened to similar drugs?

1 of 2 similar drugs in Cocaine Dependence were approved

Approved (1) Terminated (0) Active (1)
🔄Topiramate + Cognitive Behavioral Therapy + Placebo + Cognitive Behavioral TherapyJohnson & JohnsonPhase 3
✅quetiapineAstraZenecaApproved

Hype Score Breakdown

Clinical
12
Activity
8
Company
12
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00777062Phase 2Completed

Competing Products

13 competing products in Cocaine Dependence

See all competitors
ProductCompanyStageHype Score
Topiramate + Cognitive Behavioral Therapy + Placebo + Cognitive Behavioral TherapyJohnson & JohnsonPhase 3
36
TopiramateJohnson & JohnsonPhase 2
35
quetiapineAstraZenecaApproved
43
quetiapine fumarate + Matched PlaceboAstraZenecaPre-clinical
26
AFQ056 + PlaceboNovartisPhase 1
21
AFQ056 + PlaceboNovartisPhase 2
35
ALKS 33-BUP + ALKS 33 + PlaceboAlkermesPhase 1
26
vigabatrin + placeboCatalyst PharmaceuticalsPhase 2
29
Vigabatrin + Matching PlaceboCatalyst PharmaceuticalsPhase 2/3
32
Vigabatrin + PlaceboCatalyst PharmaceuticalsPhase 2
29
CPP-115 + PlaceboCatalyst PharmaceuticalsPhase 1
23
TNX-1300Tonix PharmaceuticalsPhase 2
17
TNX-1300 (Injection) + Placebo (Injection)Tonix PharmaceuticalsPhase 2
17